ArticleScientific reports2026
A bilayered microneedle patch loaded with methotrexate and dexamethasone for transdermal treatment of psoriasis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Psoriasis is a persistent inflammatory dermatological disorder characterized by dysregulated hyperproliferation of keratinocytes and pathological immune cell infiltration, impacting a significant population globally. Conventional systemic therapies, including oral and injectable formulations, are often limited by adverse off-target effects, which limit their utility in long-term clinical management. To address this challenge, we developed a soluble bilayered microneedle patch (Methotrexate and dexamethasone co-loaded bilayer microneedles, MTX@DXM-MNs), which consists of an outer layer of gelatine-polyvinyl alcohol hydrogel loaded with dexamethasone (DXM) and an inner layer of aminocrystallized hyaluronic acid methacrylate hydrogel loaded with methotrexate (MTX). The patch successfully traversed imiquimod (IMQ)-induced thickened epidermis in murine models to achieve intralesional drug delivery and effectively alleviate psoriasis-like skin inflammation. Versus tacrolimus ointment (positive control), MTX@DXM-MNs markedly alleviated the manifestations of stratum corneum thickening, erythema, and scaling in a mouse model and attenuated the levels of inflammatory mediators in skin tissues and peripheral blood as well as splenic indices. In conclusion, the MTX@DXM-MN bilayered microneedle patch provides a new strategy for the efficient and safe treatment of psoriasis through the temporal and spatial synergistic effects of an outer layer for the immediate release of a hormone and an inner layer for the slow release of an immunosuppressant. Thus, this patch has potential as a future clinical alternative for the treatment of psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.